The increased TIL TFH and B-cells, as likely observed in mice with the Treg-specific deletion of Blimp1, and tertiary lymphoid structure formation are associated with favorable outcomes in certain types of cancer and better responses to immunotherapy (106–112). The gene discussed is PRDM1; the disease is cancer.